<DOC>
	<DOCNO>NCT02250859</DOCNO>
	<brief_summary>The purpose study assess pharmakokinetic profile Minocycline FMX-101 4 % foam product male female acne</brief_summary>
	<brief_title>A Pharmacokinetic Study Minocycline Male Female Volunteers</brief_title>
	<detailed_description>This open-label , single-center , non-randomized , multiple-administrations study male female , acne . Twelve ( 12 ) subject enrol receive daily dose topical FMX-101 minocycline ( 4 % ) foam sixteen consecutive day . Each subject undergo screening procedure within 21 day prior dose , assess eligibility participate study , include dermatological assessment acne severity distribution ( subject acne ) . On Days 1 , 2 , 3 , 7 , 9 , 11 , 14 , 16 17 blood drawn PK An End-of Study/Safety Follow-up visit take place 7-10 day last dose , also include dermatological assessment response treatment</detailed_description>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Men woman 18 35 year ( inclusive ) age . 2 . Clear skin facial acne severity , currently untreated 3 . Otherwise healthy subject 4 . Subjects provide write informed consent participate study . 5 . Women childbearing potential willing use 2 reliable method contraception practice abstinence study period surgically sterilize agree undergo repeat pregnancy test . 6 . Body Mass Index ( BMI ) 19.0 &lt; 30.0 kg/m2 weight range 6090 kg ( male ) 5085 ( female ) . 7 . Nonsmoking use tobacco nicotine product ( declaration ) period least 6 month prior screen visit 8 . Subjects general good health opinion investigator determine medical history , vital sign , ECG physical examination . 9 . Shaven facial hair ( male ) 10 . Negative HIV , Hepatitis B Hepatitis C serology test screen . 11 . No clinically significant abnormality hematology , blood chemistry , urinalysis lab test screen . 12 . No known history alcohol drug abuse . Negative urinary screen drug abuse determine within 21 day start study ( screen visit ) . 13 . Willingness minimize exposure sun 20 day first dose 14 . Subjects must able understand requirement study must willing comply requirement study 1 . Documented history ongoing symptom significant neurological , renal , cardiovascular , respiratory ( asthma ) , endocrinological , gastrointestinal , hematopoietic disease , neoplasm clinically significant medical disorder , investigator 's judgment contraindicate administration study medication . 2 . Known suspected pregnancy lactation plan pregnancy study duration ( female ) 3 . Use topical antibiotic topical corticosteroid acne treatment within past 2 week . 4 . Use systemic corticosteroid within past 4 week . 5 . Use systemic retinoids ( e.g . isotretinoin ) within past 6 month . 6 . Concurrent use medication know photosensitizers possibility augment photosensitivity . 7 . History evidence skin condition acne ( eg , eczema ) would interfere subject 's participation study . 8 . Use prescription overthecounter ( OTC ) medication , vitamin herbal dietary supplement within 14 day prior dose . Paracetamol ibuprofen symptomatic relief pain allow 24 hour prior study drug administration . 9 . Dermatological condition might effect upon dermal application , e.g . : Psoriasis , mycosis fungoides , widespread acne , facial back dermatophytosis , severe hyperhydrosis , chronic recurrent skin infection , ichtyosis 10 . Excessive hair intend application area 11 . Current recent ( within 1year ) drug alcohol abuse . 12 . Known contraindication , hypersensitivity and/or allergy study drug excipients . 13 . Subjects significant allergic response drug 14 . Any acute illness ( e.g . acute infection ) within 48 hour prior first study drug administration , consider significance Principal Investigator . 15 . Participation another clinical trial drug receive within 3 month prior dose ( calculate previous study 's last dosing date ) . 16 . Subjects donate blood three month receive blood plasma derivative six month precede study drug administration . 17 . Subjects unable communicate well investigator CRC staff ( i.e. , language problem , poor mental development impair cerebral function ) . 18 . Subjects noncooperative unwilling sign consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>